Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Enterprise Value (2016 - 2025)

China Pharma Holdings' Enterprise Value history spans 16 years, with the latest figure at -$345112.0 for Q4 2025.

  • For Q4 2025, Enterprise Value rose 44.95% year-over-year to -$345112.0; the TTM value through Dec 2025 reached -$345112.0, up 44.95%, while the annual FY2025 figure was -$345112.0, 44.95% up from the prior year.
  • Enterprise Value reached -$345112.0 in Q4 2025 per CPHI's latest filing, down from -$300000.0 in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$300000.0 in Q3 2025 to a low of -$4.9 million in Q4 2021.
  • Average Enterprise Value over 5 years is -$1.4 million, with a median of -$870395.5 recorded in 2023.
  • Peak YoY movement for Enterprise Value: plummeted 642.96% in 2022, then soared 68.59% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$4.9 million in 2021, then surged by 58.22% to -$2.0 million in 2022, then grew by 29.86% to -$1.4 million in 2023, then surged by 55.97% to -$626879.0 in 2024, then skyrocketed by 44.95% to -$345112.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Enterprise Value are -$345112.0 (Q4 2025), -$300000.0 (Q3 2025), and -$625032.0 (Q2 2025).